DoD Gulf War Illness, Research Advancement Award | W81XWH 20 GWIRP RAA

Opportunity Information: Apply for W81XWH 20 GWIRP RAA

The DoD Gulf War Illness Research Advancement Award (FY20 GWIRP RAA; W81XWH-20-GWIRP-RAA) is a competitive research grant/cooperative agreement opportunity from the Department of Defense (USAMRAA/CDMRP) designed to push Gulf War Illness (GWI) work further down the translational pipeline. It focuses on applied, evidence-driven studies that expand, replicate, and validate promising biological markers and therapeutic approaches that already have some support in the existing GWI literature. The award is positioned in the program's "Qualification" stage, meaning it is meant to strengthen the case for a marker, mechanism, or intervention by building more rigorous, confirmatory data rather than starting from scratch with early discovery concepts.

A key expectation is that proposals come with preliminary data in GWI (or closely supportive data) and are built around a clear, testable hypothesis grounded in what is already known about GWI. The DoD is looking for projects with real translational potential, so applications must explain how the results could ultimately produce clinical impact for Veterans affected by GWI, even if the project itself stops short of delivering an immediate clinical change. The program is explicitly centered on Veterans from the 1990-1991 Gulf War and on core features of GWI, and applicants are expected to state plainly how their work would matter to this specific population and condition.

In terms of what the funding supports, the announcement emphasizes activities such as expanding limited datasets on candidate biomarkers, validating mechanistic targets and interventions, conducting advanced studies on "druggable" targets, identifying and optimizing lead compounds, and generating preclinical packages that could support either repurposing an already approved drug or preparing for a new Investigational New Drug (IND) submission to the FDA. If an applicant proposes testing an FDA-approved drug in an animal model, they must justify why that preclinical step is necessary instead of moving directly to a small human pilot, signaling that the program wants animal testing to be purposeful and not redundant when a human study would be more appropriate.

The FY20 Areas of Emphasis highlight topics the program is particularly interested in, while still allowing other relevant GWI ideas. Strong priority is placed on replication and validation of treatments that have already shown positive effects in GWI, along with replication and validation of suspected causes and treatment targets tied to dysregulated biological systems. The symptom and system domains called out include cognitive problems (memory, mood, behavior), non-restorative sleep and sleep disruption, chronic widespread pain, debilitating fatigue, gastrointestinal problems (including dietary intolerances, GERD, and functional GI disorders), sinus and respiratory issues, headaches, skin conditions, neurological dysfunction (central, peripheral, autonomic, and neuromuscular), immune dysfunction, endocrine/exocrine/excretory dysfunction with special attention to kidney and liver issues (including cytochrome P450 abnormalities), and microbiome differences. The announcement also encourages work on how stressors such as exertion or immune challenge worsen symptoms, and on "crosstalk" between systems (for example, immune changes influencing the nervous system or autonomic dysfunction affecting GI function) that could explain multi-system illness patterns. Another emphasized area is identifying molecular signatures (genomic, proteomic, metabolic, epigenetic) that underlie symptom clusters and may help group Veterans by shared biology. The program also flags interest in comorbidities, mortality, and differences by sex or ethnicity.

Applicants are encouraged to contribute biospecimens and data to the established GWI biorepository network known as BBRAIN (Boston Biorepository, Recruitment, and Integrative Network for GWI). The award includes an optional "Biorepository Contribution Option" that provides a slightly higher direct-cost cap for projects that meet the additional requirements and commit to contributing specimens/data, reflecting a broader program goal of building shared resources that accelerate the field.

The announcement also draws clear boundaries around what it will not fund. It excludes projects that try to derive GWI diagnostic biomarkers solely from animal models, studies of FDA-approved drugs in animals when there is already enough evidence to justify human clinical studies instead, and work that frames psychiatric disease or psychological stress as the primary cause of GWI. It does not support ALS-focused research (though Gulf War Veterans with ALS may be included if they fit the study's GWI case definition and the project remains focused on GWI symptomatology). Importantly, it does not support clinical trials as defined by prospective assignment of human subjects to interventions to measure outcomes; investigators aiming to run clinical trials are redirected to other GWIRP mechanisms such as the Clinical Evaluation Award or Therapeutic/Biomarker Trial Award.

On award structure and funding, the DoD expects to use assistance agreements, meaning awards will be issued either as grants (if the DoD anticipates no substantial involvement) or cooperative agreements (if substantial DoD involvement is expected, such as collaboration or participation during the research). For this mechanism, anticipated direct costs for the full performance period are capped at $625,000, or $645,000 with the Biorepository Contribution Option. The program anticipated roughly $3 million total to support about three awards. For the FY20 cycle described, the original application deadline was September 10, 2020, with awards expected by September 30, 2021, and FY20 funds projected to remain available for use through September 30, 2026, subject to federal funding availability and the results of scientific and programmatic review. Eligibility is listed as unrestricted, meaning a wide range of organizations may apply, provided they meet any requirements stated in the full announcement.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Gulf War Illness, Research Advancement Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Mar 24, 2020.
• Applicants must submit their applications by Sep 10, 2020. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 3 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 20 GWIRP RAA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: